Cytel Inc.
9
2
2
2
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 60/100
33.3%
3 terminated/withdrawn out of 9 trials
40.0%
-46.5% vs industry average
33%
3 trials in Phase 3/4
150%
3 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (9)
Videofluoroscopic Swallowing Study (VFSS)
Role: collaborator
Pharyngeal Electrical Stimulation Evaluation for Dysphagia After Stroke
Role: collaborator
The PhINEST Study - Pharyngeal ICU Novel Electrical Stimulation Therapy
Role: collaborator
Repurposed Approved and Under Development Therapies for Patients With Early-Onset COVID-19 and Mild Symptoms
Role: collaborator
Study to Investigate the Pharmacokinetics, Pharmacodynamics and Assess the Efficacy and Safety to Support Dose Selection of Emapalumab in Pre-empting Graft Failure in Patients at High Risk After HSCT.
Role: collaborator
A Clinical Study to Investigate Interferon Gamma (IFNɣ) Signature in Patients Post HSCT and in Patients With Impaired HSC Proliferation Pre-transplant
Role: collaborator
Study to Compare Ferric Carboxymaltose With Placebo in Patients With Acute Heart Failure and Iron Deficiency
Role: collaborator
PoC Study of OBE022 in Threatened Preterm Labour
Role: collaborator
Hydroxychloroquine and Lopinavir/ Ritonavir to Improve the Health of People With COVID-19: "The Hope Coalition - 1"
Role: collaborator
All 9 trials loaded